An analysis of outcomes from a cohort of 1,261 patients from the prospective FLEX study has shown that women with HR+/HER2- early-stage breast cancer who benefit the most from anthracycline-based chemotherapy are those with tumors classified as MammaPrint High Risk 2 and BluePrint Luminal B. February 12, 2026. Anthracycline-based chemotherapy is considered […]
Are you a healthcare professional?
This content is intended exclusively for healthcare professionals.
The content is for informational purposes only and is not intended for the general public.









